We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+46.69%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$2.05B
AUM Growth
+$352M
Cap. Flow
-$16.5M
Cap. Flow %
-0.81%
Top 10 Hldgs %
43.96%
Holding
116
New
16
Increased
40
Reduced
31
Closed
12

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$31.1M
2
AVLN
Avalyn Pharma
AVLN
+$19.1M
3
PBLS
Parabilis Medicines Inc
PBLS
+$16M
4
COAG
Hemab Therapeutics
COAG
+$15.9M
5
CYTK icon
Cytokinetics
CYTK
+$10.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$37.7M
2
ACLX
Arcellx
ACLX
+$19.5M
3
ELVN icon
Enliven Therapeutics
ELVN
+$15.4M
4
RVMD icon
Revolution Medicines
RVMD
+$15.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
76
EyePoint Inc
EYPT
$386M
$3.84M 0.19%
268,519
+9,780
+4% +$131K
OCUL icon
77
Ocular Therapeutix
OCUL
$2.28B
$3.77M 0.18%
383,716
– –
SYRE icon
78
Spyre Therapeutics
SYRE
$7.97B
$3.75M 0.18%
+42,254
New +$3.08M
TLPH icon
79
Talphera
TLPH
$62.3M
$3.7M 0.18%
3,589,186
– –
ROIV icon
80
Roivant Sciences
ROIV
$25.1B
$3.57M 0.17%
101,000
+4,000
+4% +$118K
PCVX icon
81
Vaxcyte
PCVX
$8.9B
$3.5M 0.17%
60,250
– –
NGNE icon
82
Neurogene
NGNE
$732M
$3.36M 0.16%
106,750
+2,411
+2% +$66.4K
IPSC icon
83
Century Therapeutics
IPSC
$366M
$3.2M 0.16%
1,304,347
– –
ATEC icon
84
Alphatec Holdings
ATEC
$1.46B
$3.11M 0.15%
360,000
+10,000
+3% +$91.1K
NVO
85
Novo Nordisk
NVO
$202B
$3.04M 0.15%
63,500
-26,500
-29% -$1.14M
OLMA icon
86
Olema Pharmaceuticals
OLMA
$899M
$2.94M 0.14%
235,178
+64,800
+38% +$868K
NGEN
87
NervGen Pharma
NGEN
$245M
$2.49M 0.12%
+1,208,231
New +$3.75M
MDT icon
88
Medtronic
MDT
$117B
$2.42M 0.12%
+30,900
New +$2.49M
TEVA icon
89
Teva Pharmaceuticals
TEVA
$42.5B
$2M 0.1%
59,000
+13,500
+30% +$450K
DNTH icon
90
Dianthus Therapeutics
DNTH
$5.92B
$1.98M 0.1%
20,326
-6,431
-24% -$562K
SGMT icon
91
Sagimet Biosciences
SGMT
$656M
$1.93M 0.09%
+250,000
New +$1.7M
CAPR icon
92
Capricor Therapeutics
CAPR
$558M
$1.79M 0.09%
+74,448
New +$2.26M
LENZ
93
LENZ Therapeutics
LENZ
$161M
$1.46M 0.07%
257,460
– –
ALT icon
94
Altimmune
ALT
$605M
$1.43M 0.07%
+471,465
New +$1.41M
KLRA
95
Kailera Therapeutics
KLRA
$2.1B
$1.43M 0.07%
+65,000
New +$1.43M
SGRY icon
96
Surgery Partners
SGRY
$1.79B
$1.41M 0.07%
84,000
-124,000
-60% -$1.74M
AXSM icon
97
Axsome Therapeutics
AXSM
$10.4B
$1.35M 0.07%
+5,500
New +$1.19M
ORKA
98
Oruka Therapeutics
ORKA
$6.03B
$1.15M 0.06%
12,051
+7,928
+192% +$528K
VKTX icon
99
Viking Therapeutics
VKTX
$3.75B
$995K 0.05%
25,500
-70,500
-73% -$2.28M
LEGN icon
100
Legend Biotech
LEGN
$3.87B
$967K 0.05%
33,500
-7,000
-17% -$189K
1 2 3
4
5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rock Springs Capital Management held 116 positions worth $2.05B, up 21% from $1.7B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Rock Springs Capital Management's Q2 2026 filing shows 16 new, 40 increased, 31 reduced and 12 closed positions. Its largest new stake was Avalyn Pharma: 662,918 shares worth $21.8M. The largest sale was argenx, an estimated $37.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Rock Springs Capital Management's largest Q2 2026 buy was Avalyn Pharma: 662,918 shares worth $21.8M.
  • Rock Springs Capital Management added most to Travere Therapeutics in Q2 2026, an estimated $31.1M increase.
  • Rock Springs Capital Management's biggest Q2 2026 reduction was argenx, cutting an estimated $37.7M.
  • Rock Springs Capital Management fully exited Arcellx in Q2 2026, selling an estimated $19.5M.
  • Rock Springs Capital Management's ten largest holdings make up 44% of its $2.05B portfolio in Q2 2026.
  • Rock Springs Capital Management opened 16 new positions and closed 12 in Q2 2026.
  • Rock Springs Capital Management's portfolio value rose 21% quarter-over-quarter to $2.05B.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.